Cocrystal Pharma (COCP) Stock Price, News & Analysis

Company Overview

Cocrystal Pharma, Inc. (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections. Lead projects target influenza A and B polymerases as well as key enzymes in coronaviruses such as SARS-CoV-2. Additional research efforts are directed at antiviral targets in hepatitis B virus, norovirus and other emerging viral threats, reflecting Cocrystal’s commitment to addressing a broad spectrum of infectious diseases.

Founded in 2006 and headquartered in Bothell, Washington, Cocrystal Pharma leverages collaborations with academic institutions and contract research organizations to expand its drug discovery capabilities. The company maintains research laboratories in the Seattle area and operates a business development office in New York City to engage with strategic partners and investors globally.

Under the leadership of founder and Chief Executive Officer Kenneth T. Hitchcock, Ph.D., Cocrystal Pharma seeks to address unmet medical needs in antiviral therapy. By combining deep structural biology expertise with a scalable discovery engine, the company aims to advance novel antivirals poised to combat both seasonal outbreaks and future pandemic threats.

Key Stats

• Today's Range: $1.04 to $1.07
• 50-Day Range: $1.05 to $1.70
• 52-Week Range: $1.02 to $3.26
• Volume: 89,213 shs
• Average Volume: 351,692 shs
• Market Capitalization: $10.78 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $6.00
• Consensus Rating: Hold

Cocrystal Pharma Stock Analysis - MarketRank™

Cocrystal Pharma scored higher than 33% of companies evaluated by MarketBeat, and ranked 784th out of 950 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Cocrystal Pharma has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

Cocrystal Pharma has a consensus price target of $6.00, representing about 471.4% upside from its current price of $1.05.

Amount of Analyst Coverage

Cocrystal Pharma has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Cocrystal Pharma are expected to decrease in the coming year, from ($1.85) to ($2.16) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Cocrystal Pharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Cocrystal Pharma is -0.85, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Cocrystal Pharma has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

11.01% of the float of Cocrystal Pharma has been sold short.

Short Interest Ratio / Days to Cover

Cocrystal Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cocrystal Pharma has recently increased by 2,281.55%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Cocrystal Pharma does not currently pay a dividend.

Dividend Growth

Cocrystal Pharma does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

11.01% of the float of Cocrystal Pharma has been sold short.

Short Interest Ratio / Days to Cover

Cocrystal Pharma has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Cocrystal Pharma has recently increased by 2,281.55%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.6 / 5
• News Sentiment: 0.64

News Sentiment

Cocrystal Pharma has a news sentiment score of 0.64. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Cocrystal Pharma this week, compared to 1 article on an average week.

Search Interest

3 people have searched for COCP on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Cocrystal Pharma insiders have not sold or bought any company stock.

Percentage Held by Insiders

28.14% of the stock of Cocrystal Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

Only 6.72% of the stock of Cocrystal Pharma is held by institutions.

COCP Stock Analysis - Frequently Asked Questions

How have COCP shares performed this year?

Cocrystal Pharma's stock was trading at $2.02 on January 1st, 2025. Since then, COCP stock has decreased by 48.0% and is now trading at $1.05.

How were Cocrystal Pharma's earnings last quarter?

Cocrystal Pharma, Inc. (NASDAQ:COCP) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.20) earnings per share for the quarter, beating the consensus estimate of ($0.30) by $0.10.

When did Cocrystal Pharma's stock split?

Cocrystal Pharma shares reverse split on the morning of Tuesday, October 11th 2022.The 1-12 reverse split was announced on Tuesday, October 11th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, October 11th 2022. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

How do I buy shares of Cocrystal Pharma?

Shares of COCP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Cocrystal Pharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Cocrystal Pharma investors own include NVIDIA (NVDA), Meta Platforms (META), OPKO Health (OPK), Advanced Micro Devices (AMD), NIO (NIO), CrowdStrike (CRWD) and Pfizer (PFE).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 10/15/2025
• Next Earnings (Estimated): 11/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:COCP
• CIK: 1412486
• Web: www.cocrystalpharma.com
• Phone: (305) 425-1780
• Fax: N/A
• Employees: 10
• Year Founded: 2004

Price Target and Rating

• Average Price Target for Cocrystal Pharma: $6.00
• High Price Target: $6.00
• Low Price Target: $6.00
• Potential Upside/Downside: +460.7%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.24)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$17.50 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -144.12%
• Return on Assets: -102.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.69
• Quick Ratio: 3.69

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.94 per share
• Price / Book: 1.14

Miscellaneous

• Outstanding Shares: 10,270,000
• Free Float: 7,384,000
• Market Cap: $10.99 million
• Optionable: Not Optionable
• Beta: 2.25